NCT04192136Completed
NAD+ and Exercise in FA
NAD+ Precursor Supplementation With Exercise Training to Increase Aerobic Capacity in Friedreich's Ataxia
Source: ClinicalTrials.gov · Last updated 11 Mar 2026
Brief summary (registry, in English)
Randomized, placebo-controlled trial with a 2x2 factorial design testing the effects of an NAD+ precursor (NR) and exercise on Peak VO2 and Si in Friedreich's Ataxia (FA). The primary objective of this research is to measure the effect of combination administration (NR + exercise) on aerobic capacity (Peak VO2) in FA. A key secondary objective is to measure the effect of combination administration (NR + exercise) on glucose homeostasis (Si) in FA.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 75 (actual)
- First submitted
- 6 Dec 2019
- Start date
- 3 Sept 2020
- Primary completion date
- 7 Feb 2025
- Lead sponsor
- Children's Hospital of Philadelphia
- Diseases
- Friedreich ataxia
- NCT number
- NCT04192136
What you commit to
- Study type: Interventional
- Participants enrolled: 75
- From 3 Sept 2020 to the primary completion date, 7 Feb 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent use of any medications, including statins, likely to increase risk of NR toxicity.
- Use of supraphysiologic steroids.
- Use of any investigational agent within 4 weeks of enrollment, except open-label extension phase.
Other illness
- HgbA1c \> 8.5% and/or Diabetes Mellitus (DM) requiring insulin or insulin secretagogue.
- Uncontrolled and persistent arrhythmias that are felt to be clinically significant.
- Any contraindication to MRI. Including:
- Any intra-luminal implant, filter, stent or valve replacement
- Any type of life assist device, pump, or prosthetic
- Any vascular clip or clamp
- Any surgically placed clips or clamps or bands on visceral organs
- Any intracranial implants of any type other than dental fillings
- Any non-removable piercings, jewelry, or medicinal patch
- Any personal history of intraocular injury or fragment in or around the orbit that cannot be cleared through radiologic examination.
- Any personal history of bullet, shrapnel, or stabbing wounds that cannot be cleared through radiologic evaluation.
- Inability to lie flat in the MRI scanner for 60-90 minutes.
- participants who cannot complete the MRI will not be excluded from participation in the remainder of the study procedures if they meet those inclusion and exclusion criteria
- Any medical condition, in the opinion of the investigator that will interfere with the safe completion of the study.
Lab values
- Laboratory abnormalities that indicate clinically significant anemia or bleeding risk. (Hemoglobin \< 10 g/dL or Platelets \< 100K)
- Laboratory abnormalities that indicate clinically significant kidney disease using serum creatinine and Modification of Diet in Renal Disease (MDRD) equation. (Estimated Glomerular Filtration Rate (eGFR) \< 60 ml/min/1.73 m2)
- Laboratory abnormalities that indicate clinically significant liver disease. (Aspartate Aminotransferase (AST)/Serum Glutamic Oxaloacetic Transaminase (SGOT) 3.0 x Upper Limit of Normal and/or Alanine Aminotransferase (ALT)/Serum Glutamic Pyruvic Transaminase (SGPT) 3.0 x Upper Limit of Normal)
- Known history of moderate or severe left ventricular systolic dysfunction (Left Ventricular Ejection Fraction (LVEF) \< 45%)
Other
- Known sensitivity to NR.
- Standard contraindications to exercise testing.
- Inability to sit and pedal unassisted in a cycle ergometry chair, at a cadence of at least 55 rotations per minute (rpm) during unloaded warm up, in a cycle ergometry chair and complete a maximal Cardio Pulmonary Exercise Test (CPET)
- Inability to sit and pedal unassisted in a recumbent tricycle.
- Females: pregnant, lactating, or planning to become pregnant during their participation.
- Parents/guardians or participants who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.
Who the study is looking for
- Molecular diagnosis of Friedrich's Ataxia (FA).
- Males and Females, Age 10 to 40 years (inclusive).
- Girls, 11 years of age and older, must have a negative urine/serum pregnancy test and must use an acceptable method of contraception, including abstinence, a barrier method (diaphragm or condom), Depo-Provera, or an oral contraceptive, for the duration of the study.
- Not currently meeting exercise guidelines as outlined by The Physical Activity Guidelines for Americans.
- Children and Adolescents should do 60 minutes (1 hour) or more of moderate-to-vigorous physical activity daily.
- As a part of their physical activity, children and adolescents should include muscle-strengthening physical activity on at least 3 days a week.
- Adults should do at least 150 minutes (2 hours and 30 minutes) to 300 minutes (5 hours) a week of moderate-intensity, or 75 minutes (1 hour and 15 minutes) to 150 minutes (2 hours and 30 minutes) a week of vigorous-intensity aerobic physical activity.
- Adults should also do muscle-strengthening activities of moderate or greater intensity that involve all major muscle groups on 2 or more days a week.
- Cardiac echocardiogram or cardiac MRI, performed within 1 year of enrollment, showing an LVEF \> 45%
- ECG, performed within 1 year of enrollment, without clinically significant arrhythmia.
- Weight \> 24 kg
- Parental/guardian permission (informed consent) and if appropriate, child assent.
Age in the registry: 10 years to 40 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Children's Hospital of Philadelphia Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.